What is B. Riley’s Forecast for Inogen Q2 Earnings?

Inogen, Inc (NASDAQ:INGN) – Equities research analysts at B. Riley issued their Q2 2025 earnings per share estimates for shares of Inogen in a research report issued to clients and investors on Sunday, June 15th. B. Riley analyst A. Schock forecasts that the medical technology company will earn ($0.22) per share for the quarter. B. Riley has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for Inogen’s current full-year earnings is ($1.73) per share. B. Riley also issued estimates for Inogen’s Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($0.95) EPS, Q1 2026 earnings at ($0.22) EPS, Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($0.72) EPS.

INGN has been the subject of a number of other research reports. Needham & Company LLC raised shares of Inogen from a “hold” rating to a “moderate buy” rating and set a $12.00 target price for the company in a research report on Thursday, May 22nd. Stifel Nicolaus decreased their price objective on Inogen from $10.00 to $7.00 and set a “hold” rating for the company in a report on Thursday, May 8th. Finally, Wall Street Zen cut Inogen from a “buy” rating to a “hold” rating in a report on Wednesday, February 26th.

Inogen Stock Down 1.8%

Shares of INGN opened at $6.48 on Wednesday. The stock has a market capitalization of $174.25 million, a P/E ratio of -5.63 and a beta of 1.64. Inogen has a twelve month low of $5.70 and a twelve month high of $13.33. The company has a 50 day moving average of $6.66 and a 200-day moving average of $8.30.

Inogen (NASDAQ:INGN) last posted its quarterly earnings data on Wednesday, May 7th. The medical technology company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.27. The business had revenue of $82.28 million during the quarter, compared to the consensus estimate of $79.57 million. Inogen had a negative return on equity of 14.76% and a negative net margin of 8.08%.

Hedge Funds Weigh In On Inogen

Hedge funds and other institutional investors have recently made changes to their positions in the company. AlphaQuest LLC bought a new position in Inogen during the fourth quarter worth about $43,000. Meeder Asset Management Inc. bought a new position in shares of Inogen during the 4th quarter worth approximately $56,000. Integrated Wealth Concepts LLC bought a new position in shares of Inogen during the 1st quarter worth approximately $85,000. Algert Global LLC bought a new position in Inogen during the first quarter worth $89,000. Finally, Integrated Quantitative Investments LLC bought a new position in Inogen during the fourth quarter worth $92,000. 89.94% of the stock is owned by institutional investors.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.